Assessment of response to neoadjuvant chemotherapy in advanced ovarian cancer: does the level of CA125 predict an optimal debulking surgery?

被引：0
|
作者：
Ben Ltaief, Sarra [1 ]
Bouhani, Malek [1 ]
Mbarek, Mohamed Mahdi Ben [1 ]
Sakhri, Saida [1 ]
Bouaziz, Hanen [1 ]
Ben Dhiab, Tarek [1 ]
机构：
[1] Inst Salah Aziez Tunisia, Surg Oncol, Tunis Ville, Tunisia
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.345
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EV226/#752
引用
收藏
页码：A200 / A200
页数：1
相关论文
共 50 条
  • [41] CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Furukawa, Naoto
    Sasaki, Yoshikazu
    Shigemitsu, Aiko
    Akasaka, Juria
    Kanayama, Seiji
    Kawaguchi, Ryuji
    Kobayashi, Hiroshi
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 141 - 145
  • [42] Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer
    Fagotti, Anna
    Scambia, Giovanni
    LANCET ONCOLOGY, 2018, 19 (12): : 1558 - 1560
  • [43] CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer
    Memarzadeh, S
    Lee, SB
    Berek, JS
    Farias-Eisner, R
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (02) : 120 - 124
  • [44] NEOADJUVANT CHEMOTHERAPY OR FIRST LINE DEBULKING SURGERY IN ADVANCED OVARIAN CANCERS
    Chekman, Chemseddine
    Gouaref, Fatiha
    Bentabak, Kamel
    Hadjarrab, Fatiha
    Bouzid, Kamel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A127 - A127
  • [45] Comparison of differences between neoadjuvant chemotherapy and conventional chemotherapy for ovarian cancer in application, CA125 and prognosis
    Zuo, Ying
    You, Dong
    Liu, Jianhui
    Ren, Ruizhen
    Li, Ling
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (05): : 4991 - 4997
  • [46] Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Jorge A. Alegría-Baños
    José C. Jiménez-López
    Arely Vergara-Castañeda
    David F. Cantú de León
    Alejandro Mohar-Betancourt
    Delia Pérez-Montiel
    Gisela Sánchez-Domínguez
    Mariana García-Villarejo
    César Olivares-Pérez
    Ángel Hernández-Constantino
    Acitlalin González-Santiago
    Miguel Clara-Altamirano
    Liz Arela-Quispe
    Diddier Prada-Ortega
    Journal of Ovarian Research, 14
  • [47] PRIMARY DEBULKING SURGERY (PDS) VERSUS NEOADJUVANT CHEMOTHERAPY FOLLOWED BY INTERVAL DEBULKING SURGERY (IDS) FOR PATIENTS WITH ADVANCED OVARIAN CANCER
    Obeidat, R.
    Saidi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [48] Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Alegria-Banos, Jorge A.
    Jimenez-Lopez, Jose C.
    Vergara-Castaneda, Arely
    Cantu de Leon, David F.
    Mohar-Betancourt, Alejandro
    Perez-Montiel, Delia
    Sanchez-Dominguez, Gisela
    Garcia-Villarejo, Mariana
    Olivares-Perez, Cesar
    Hernandez-Constantino, Angel
    Gonzalez-Santiago, Acitlalin
    Clara-Altamirano, Miguel
    Arela-Quispe, Liz
    Prada-Ortega, Diddier
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [49] Continuing neoadjuvant chemotherapy until CA-125 reaches the nadir improves complete cytoreduction by interval debulking surgery in patients with advanced epithelial ovarian cancer
    Nakamura, K.
    Kitahara, Y.
    Ibuki, Y.
    Kogure, K.
    Kigure, K.
    Hirakawa, T.
    Kanuma, T.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 99 - 99
  • [50] Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer
    Chudecka-Glaz, Anita Monika
    Cymbaluk-Ploska, Aneta Alicja
    Menkiszak, Janusz Leszek
    Sompolska-Rzechula, Agnieszka Monika
    Toloczko-Grabarek, Aleksandra Izabela
    Rzepka-Gorska, Izabella Anna
    JOURNAL OF OVARIAN RESEARCH, 2014, 7
12345